Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

V3 variation in HIV-seropositive patients receiving a V3- targeted vaccine.

AIDS (London, England) - 30 Mar 2001

Lenz J, Su M, Mizrachi Y, Burke M, Rubinstein A

Abstract excerpt

OBJECTIVE: To analyze V3 loop sequences of HIV-1 in three seropositive individuals who exhibited declines in viremia while receiving a V3-targeted vaccine. DESIGN: Retrospective analysis of case series at an HIV Clinic, University of Tel Aviv. PATIENTS: Three HIV-1-seropositive, PPD-DTHR-positive (PPD, Siebert purified protein derivative of tuberculin; DTHR, delayed type hypersensitivity reaction) individuals who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AIDS Vaccines
Share to Amino Acid Sequence
Share to HIV-1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp120

Share to HIV Seropositivity

Share to Molecular Sequence Data

Share to Peptide Fragments

Share to Vaccines, Synthetic

Source

Identifiers

PMID: 11316994
DOI: 10.1097/00002030-200103300-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

V3 variation in HIV-seropositive patients receiving a V3- targeted vaccine.PMID 11316994Read ↗

V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1-infected patients.Semantic proximity Read ↗

Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNASemantic proximity Read ↗

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.Semantic proximity Read ↗

Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.Semantic proximity Read ↗

HIV-1 neutralization directed to epitopes other than linear V3 determinants.Semantic proximity Read ↗

Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.Semantic proximity Read ↗

Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.Semantic proximity Read ↗

Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various CladesSemantic proximity Read ↗

The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies.Semantic proximity Read ↗

Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.Semantic proximity Read ↗

V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro.Semantic proximity Read ↗

Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.